vimarsana.com

Latest Breaking News On - Caitlin kontulis - Page 1 : vimarsana.com

Phio Pharmaceuticals Announces Dosing of First Patient in

Trial targeting treatment of metastatic melanoma and other solid tumors.

United statesBridge viewBrendan curtiRobert bittermanCaitlin kontulisMichael adamsRobertw franzJudith ann hartmannAndrew weinbergProvidence cancer institute of oregonJoseph healthEarlea chiles research instituteClinical researchProvidence cancer institute in portlandLaboratory of basic immunologyPhio pharmaceuticals corp

Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc and Providence Cancer Institute

MARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose pr.

United statesBridge viewRobertw franzRobert bittermanBrendan curtiCaitlin kontulisMichael adamsJudith ann hartmannAndrew weinbergEarlea chiles research instituteLaboratory of basic immunologyJoseph healthClinical researchAgonox incProvidence cancer institute of oregonProvidence cancer institute in portland

Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc and Providence Cancer Institute - Phio Pharma (NASDAQ:PHIO)

MARLBOROUGH, Mass., Aug. 21, 2023 (GLOBE NEWSWIRE) Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make

United statesBridge viewRobertw franzMichael adamsJudith ann hartmannCaitlin kontulisAndrew weinbergBrendan curtiRobert bittermanProvidence cancer institute of oregonPhio pharmaceuticalsPhio pharmaceuticals corpClinical researchLaboratory of basic immunologyJoseph healthProvidence cancer institute in portland

vimarsana © 2020. All Rights Reserved.